Molecular biology and neurobiology of choline acetyltransferase

In the 45 years since the first description of choline acetyltransferase (ChAT; EC 2.3.1.6.), significant progress has been made in characterizing the molecular properties of this important neurotransmitter synthetic enzyme. We are now on the verge of understanding its genetic regulation and biological function(s). The Drosophila cDNA has been cloned, sequenced, and expressed in both a eucaryotic and a procaryotic system. The levels of ChAT specific mRNA have been determined during Drosophila development. Monoclonal and polyclonal antibodies have been produced to the enzyme from a variety of sources and used for biochemical and immunocytochemical studies. Two well characterized genetic systems have identified the ChAT gene and described a series of useful alleles. As a nervous system specific protein expressed only in the subset of neurons using acetylcholine as a neurotransmitter, ChAT is a good model for uncovering the processes and factors responsible for regulating genes involved in neurotransmitter phenotype selection and maintenance. Recent studies have described the purification of a cholinergic factor from muscle conditioned medium and indicated the potential importance of nerve growth factor (NGF) for regulating ChAT expression in the central nervous system. These factors, or ones remaining to be discovered, may be involved in the etiology or disease process of neurodegenerative nervous system disorders such as Alzheimer's disease.

Normal development and effects of early deafferentation on choline acetyltransferase, substance P and serotonin-like immunoreactivity in the interpeduncular nucleus

The normal postnatal development and response to neonatal fasciculus retroflexus (FR) lesions of serotonin, substance P (SP), and choline acetyltransferase (ChAT) distribution are described for the rat interpeduncular nucleus (IPN). Serotonin-, SP- and ChAT-containing axons differed in development, distribution, and response to deafferentation. Serotonergic axons and cell bodies were present at birth. SP was present in the FR and in the lateral subnuclei by 3 days of age but did not appear in the rostral or dorsal subnuclei until 7-14 days. Intrinsic SP perikarya were not seen until 17 days of age. The development of ChAT was late, appearing only during the second week of life and not reaching adult patterns and density until after 21 days of age. The pattern of development of cytochrome oxidase and Bodian silver staining are also described. Both cytochrome oxidase and Bodian staining paralleled the patterns of localization and development of ChAT staining. Bilateral neonatal FR lesions resulted in a permanent loss of ChAT and cytochrome oxidase staining throughout the IPN and of SP in the lateral and rostral subnuclei. No changes were seen in the serotonergic system. Following unilateral lesions, the pattern of SP loss and replacement paralleled that seen after adult lesions. The pattern of replacement of ChAT differed from that after adult lesions in that there was partial replacement in the ipsilateral intermediate subnucleus following neonatal lesions. This result suggests that late developing cholinergic axons can innervate the contralateral intermediate nucleus to a much greater extent following infant lesions than following adult lesions.

Neurotransmitters and memory: Role of cholinergic, serotonergic, and noradrenergic systems

In Alzheimer's disease (AD), pathological changes are found in the basal forebrain cholinergic system (BFCS), serotonergic raphe (RA), and noradrenergic locus coeruleus (LC) systems. The present study was designed to determine the extent to which selective damage in each of these systems individually could produce an impairment of memory, one of the clinical symptoms of AD. Rats were given selective lesions by injecting ibotenic acid into the nucleus basalis magnocellularis and medial septal area (i.e., BFCS); 5,7-dihydroxytryptamine into the medial and dorsal RA; and 6-hydroxydopamine (6-OHDA) into the LC or by ip injections of (2-chloroethyl)N-ethyl-2-bromobenzylamine HCl (DSP4). Levels of choline acetyltransferase (ChAT), norepinephrine, and serotonin verified lesion effectiveness and selectivity. Chronic changes in serotonergic-2 and beta-adrenergic receptors were also determined. Rats were tested in a delayed spatial alternation in a T-maze. BFCS lesions impaired choice accuracy with intertrial delays of 5, 30, and 60 s. RA lesions or DSP4 injections impaired choice accuracy only when the intertrial delay was 60 s. LC lesions (by 6-OHDA) did not impair choice accuracy at any delay. The results suggest that the pathological changes in the BFCS and RA are sufficient to produce the types of memory impairments associated with dementia, but the quantitative effects of pathology in these two systems are different.

Cholinergic function and memory: extensive inhibition of choline acetyltransferase fails to impair radial maze performance in rats

The present study investigated the effects of a potent inhibitor of choline acetyltransferase (ChAT), BW813U, on the choice accuracy of rats in the radial arm maze. BW813U (100 mg/kg, IP) produced a rapid (within 1 hour) and substantial decrease in ChAT activity throughout the brain, ranging from 66% (hippocampus) to 80% (caudate nucleus) that lasted up to 5 days. A single injection (50 mg/kg, IP) into rats with lesions (using ibotenic acid) in the nucleus basalis magnocellularis and medial septal area, decreased ChAT activity by 75% and 60% in the cortex and hippocampus, respectively. Lesioned and unlesioned rats were trained on the radial arm maze until they reached a criterion level of performance. Each rat then received an injection of BW813U (50 or 100 mg/kg, IP). Choice accuracy was not impaired at any time following the injection. The lack of effect on performance may be due to 2 possible factors: The radial maze retention paradigm chosen may not be sufficiently difficult, or the decrease in acetylcholine production was not sufficient to affect behavior. Compensation by non-cholinergic neural systems might account for the insensitivity of the rats to significant cholinergic depletion.

The mechanism of botulism

Botulism is induced by botulinum toxin and the mechanism of the disease is unknown. In another study, a fatal autoimmune disease was produced in animals by immunization with a fraction of choline acetyltransferase. When these two syndromes are compared, numerous similarities are observed. It is postulated that botulism toxin acts as an initiator for the autoimmune disease by catalyzing in vivo the formation of the pathogenic fraction of choline acetyltransferase.

Expression of cholinergic markers in the developing chick embryo spinal cord

The expression of cholinergic neurotransmission in the developing spinal cord was followed with pre- and postsynaptic cholinergic markers and histoautoradiographic determinations of cholinergic receptors and ultrastructural studies. Two distinct steps in the development of cholinergic markers were evident. The first step of cholinergic expression occurs early in development and its characterized by a sudden and large increase in choline acetyltransferase activity, whereas the high affinity choline uptake mechanism remains undetectable and few muscarinic receptors are detectable. This phenomenon possibly reflects the expression of high choline acetyltransferase gene activity in developing neurons which are still not synaptically connected. The second step is also characterized by a sharp rise of choline acetyltransferase activity. This rise parallels an active development of high affinity choline uptake and big increase in both number and density of muscarinic receptors. Also nicotine receptors increase, as revealed by histoautoradiography. Specific morphogenetic events, such as the increase of synaptic junctions with postsynaptic thickenings and numerous presynaptic clear vesicles, occur at the same time. Such interactions may contribute to the full maturity of cholinergic neurotransmission of the spinal cord.

Neurobiological studies of transmitter systems in aging and in Alzheimer-type dementia

Dysfunction and death of specific neuronal systems are important processes occurring in aging and in Alzheimer's and in Parkinson's disease. The neuropathology and neurochemistry of some of the neuronal systems at risk in these settings are subjects of active research; the nature and consequences of these cellular pathologies have begun to be clarified. The availability of animal models (including aged monkeys, macaques with cholinergic deficiencies, and monkeys with MPTP-induced nigrostriatal pathology, all of which recapitulate certain features of human aging or disease) allow the opportunity to assess the efficacies of new pharmacotherapies, neural grafts, and trophic factors. These approaches can be monitored by behavioral testing and, in some instances, by in vivo imaging methods, which can in turn be correlated with morphologic and chemical analyses of brain. Demonstration of the efficacy of these procedures in nonhuman primates would have profound implications on the development of new therapies designed to alleviate the effects of aging and disease on the human brain.

Physostigmine reverses memory deficits produced by pretraining electrical stimulation of the dorsal hippocampus in mice

The aim of the present experiments was to test the validity of the hypothesis that presynaptic cholinergic activity has a functional significance for memory formation. The results show that electrical stimulation of the dorsal hippocampus delivered before learning in BALB/c mice which induces a decrease of about 40% in hippocampal choline acetyltransferase (ChAT) activity at the time of learning results in deficits in retention scores in two appetitive learning tasks (operant conditioning in the Skinner box or a spatial memory task using a 4-hole board). In both behavioral tasks intraventricular injection of 1 microgram of physostigmine 20 min before the acquisition session reverses the disruptive effect of pretraining hippocampal stimulation. Our results seem to indicate that the memory deficits produced by pretraining electrical stimulation of the hippocampus result from both a decrease in ChAT activity and a corresponding reduction of acetylcholine availability in the hippocampal formation.

Decrease in both choline acetyltransferase activity and EEG patterns in the hippocampal formation of the rat following septal macroelectrode implantation

A decrease in both choline acetyltransferase (CAT) activity and theta (theta) rhythm were observed in the hippocampal formation of rats implanted with a macroelectrode in the dorsomedial part of the septum. The decrease in CAT activity and in theta occurred simultaneously and in parallel, and there was no instance where the two parameters were uncoupled. These observations suggest that a common neurophysiological mechanism is involved in both CAT activity control and theta rhythm production in the hippocampal formation. From a methodological point of view, these observations should be borne in mind in septohippocampal investigations using septal electrode implantation procedures.

Choline and cholinergic neurons

Mammalian neurons can synthesize choline by methylating phosphatidylethanolamine and hydrolyzing the resulting phosphatidylcholine. This process is stimulated by catecholamines. The phosphatidylethanolamine is synthesized in part from phosphatidylserine; hence the amino acids methionine (acting after conversion to S-adenosylmethionine) and serine can be the ultimate precursors of choline. Brain choline concentrations are generally higher than plasma concentrations, but depend on plasma concentrations because of the kinetic characteristics of the blood-brain-barrier transport system. When cholinergic neurons are activated, acetylcholine release can be enhanced by treatments that increase plasma choline (for example, consumption of certain foods).

Choline acetyltransferase in cerebral arteries: modulator of amino acid uptake?

The possibility exists that synthesis of acetylcholine in cerebral blood vessels does not reflect the presence of cholinergic nerves, but is the property of some other cell type. Therefore, the hypothesis that acetylcholine synthesis in cerebral arteries modulates amino acid transport was tested. Choline acetyltransferase activity in rabbit cerebral arteries was inhibited by (2-benzoylethyl) trimethylammonium chloride. Furthermore, the product formed in this assay was degraded by added acetylcholinesterase, confirming the authenticity of measurements of choline acetyltransferase. Rabbit pial arteries (basilar and middle cerebral) accumulated alpha-aminoisobutyric acid to a greater extent than peripheral arteries. Ouabain (10(-5) M) blocked this accumulation, suggesting that it is analogous to the A-system for amino acid transport. (2-benzoylethyl) Trimethylammonium chloride showed a concentration dependent inhibition of alpha-aminoisobutyric acid accumulation in cerebral arteries, but was without effect on peripheral arteries. Atropine and physostigmine in concentrations as high as 10(-6) M had no significant effects on alpha-aminoisobutyric acid accumulation. An association between choline acetyltransferase activity and amino acid uptake is apparent in the cerebral vasculature, suggesting that synthesis of acetylcholine may be involved in modulation of the blood-cerebrospinal fluid barrier. This finding underscores the uncertainty of assuming that acetylcholine synthesis necessarily indicates the presence of cholinergic nerves.

The influence of supraspinal impulse activity on the intra-axonal transport of transmitter-related substances in rat motor neurons

The content and intra-axonal transport of acetylcholine (ACh) and the ACh-metabolizing enzymes choline-acetyl-transferase (CAT) and ACh-esterase (AChE) in the rat sciatic nerve were studied after various experimental procedures. The procedures involved: (1) spinal cord transection (SCT) at the thoracic level 1 day to 3 weeks prior to experiments, to abolish nerve activity of the lower motor neurons (in the lumbar intumescence-sciatic nerve) from supraspinal centres; (2) physical training for 2 h daily during 2 weeks in a rodent treadmill, to increase nerve activity from supraspinal levels; and (3) the use of selective neurotoxins to cause degeneration of descending bulbospinal monoaminergic (MA) neurons. The results of these studies demonstrate that supraspinal nerve influence can modify the axonal transport of ACh and cholinergic enzymes in the rat sciatic nerve, and that descending monoamine (MA) pathways may, at least to some extent, participate in this modulation of intraneuronal dynamics in the motor neuron. Since it has been shown by many investigators that factors which have a trophic influence on skeletal muscle cells both in vitro and in vivo are present in motor nerves and transported along the axons in a distal direction, we suggest that the synthesis and axonal transport of such factors may also be under control of supraspinal nerve activity. Therefore, it is possible that metabolic changes and dystrophy of muscles occurring in patients with lesions of the 'upper motor neuron-type' may also, in addition to other factors, be dependent on changes in intra-axonal transport of various substances in the lower motor neuron.